Aurobindo Pharma Share Price
(AUROPHARMA)
₹1058.3
as on 04:01PM, 28 Feb 2025
Aurobindo Pharma Performance
Day's Low
Day's High
₹1,053.3Day's Price Range₹1,076.3552 Week's Low
52 Week's High
₹984.352-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | -7.38 % |
| 3 Month Return | -15.66 % |
| 1 Year Return | + 3.11 % |
| Market Stats | |
| Previous Close | ₹1,080.70 |
| Open | ₹1,075.90 |
| Volume | 7.95L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹62,009.88Cr |
Aurobindo Pharma Key Statistics
P/E Ratio
17.71
PEG Ratio
1.42
Market Cap
₹62,009.88 Cr
P/B Ratio
3.24
EPS
54.09
Dividend Yield
0.41
Sector
Pharmaceuticals
ROE
10.35
Aurobindo Pharma Mutual Fund Holdings
Aurobindo Pharma Analyst Rating
based on 28 analysts
78.57%
Buy
7.14%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1504.46
Source: S&P Global Market Intelligence
Aurobindo Pharma Share analysis
Aurobindo Pharma price forecast by 28 analysts
Upside of42.16%
High
₹1930
Target
₹1504.46
Low
₹1145
Aurobindo Pharma target price ₹1504.46, a slight upside of 42.16% compared to current price of ₹1058.3. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:28.71%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:51.44%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Aurobindo Pharma Ltd
Aurobindo Pharma Acquires Majority Stake in Tergene Biotech - 28 Feb, 2025
Aurobindo Pharma has successfully acquired an 80% stake in Tergene Biotech, transitioning it to a direct subsidiary effective February 26, 2025.Aurobindo Pharma Faces FDA Scrutiny Amid Buy Recommendation - 20 Feb, 2025
Aurobindo Pharma's New Jersey warehouse received an OAI status from the FDA after an inspection, leading to a 1.49% stock decline. Despite this, a buy recommendation emerged, suggesting potential recovery.Aurobindo Pharma Faces FDA Observations Post Inspection - 18 Feb, 2025
Aurobindo Pharma's Eugia Steriles facility received five procedural observations from the US FDA after a pre-approval inspection. The company plans to address these observations promptly.Aurobindo Pharma Begins European Supplies from China - 16 Feb, 2025
Aurobindo Pharma announced plans to start supplying the European market from its China facility in April 2025, following regulatory approvals. The company anticipates significant growth from this operation over the next few years, despite a recent dip in net profit.Aurobindo Pharma Secures EU Approval for Biosimilar - 14 Feb, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received marketing authorization from the European Commission for Zefylti, a filgrastim biosimilar, following a positive opinion from the CHMP.Aurobindo Pharma Positioned for Growth Amid Tariffs - 12 Feb, 2025
Aurobindo Pharma is set to benefit from US tariffs on Chinese imports, enhancing its market position. With a strong presence in the US and Europe, the company plans to launch over 40 new products, supported by robust R&D efforts. Revenue and profit growth of 4.7% and 2.2% respectively over the last five years indicate a positive outlook.Aurobindo Pharma Receives Upgrades Amid Market Challenges - 11 Feb, 2025
Aurobindo Pharma faces a 2.39% drop in share price, but analysts upgrade the stock to Buy, citing growth potential and a revised target price of Rs 1,510. The company is positioned well for future growth despite recent performance challenges.Aurobindo Pharma Faces Tariff Concerns, Target Price Adjusted - 10 Feb, 2025
Aurobindo Pharma's stock faced pressure from concerns about potential US tariffs on pharma imports. ICICI Securities maintains a 'BUY' rating but lowers the target price to Rs 1,445 due to disappointing Q3FY25 performance and lower US sales expectations.Aurobindo Pharma Reports Mixed Q3 Results and Acquisitions - 07 Feb, 2025
Aurobindo Pharma's Q3 FY25 results show a 9.7% decline in net profit to Rs 846 crore, despite an 8.5% revenue increase. The company also received VAI classification from the US FDA for its API Unit 2 and plans to acquire an 80% stake in Tergene Biotech.Aurobindo Pharma Reports Q3 Results and Acquisition Plans - 06 Feb, 2025
Aurobindo Pharma's board approved acquiring an 80% stake in Tergene Biotech. The company reported a 10% decline in Q3 net profit to ₹846 crore due to lower U.S. revenue.Aurobindo Pharma Faces Significant GST Demand - 05 Feb, 2025
Aurobindo Pharma has received a GST demand and penalty exceeding ₹155 crore, related to excess IGST refunds and non-reversal of ITC. The company plans to appeal.Aurobindo Pharma Stock Recommended for Purchase - 03 Feb, 2025
Aurobindo Pharma is recommended for purchase at 1348, with target prices of 1405-1426, reflecting optimism due to recent bullish trends in the Pharma sector.Aurobindo Pharma's Subsidiary Gains Positive CHMP Opinion - 01 Feb, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a positive opinion from the CHMP within the EMA for Dyrupeg, paving the way for marketing authorization.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 6.46% to 6.69% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 57.4% return, outperforming this stock by 54.3%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 112.7% return, outperforming this stock by 42.0%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 18.53% to 17.81% in Dec 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.59% to 16.29% in Dec 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, AUROPHARMA stock has moved down by -7.4%
News
Aurobindo Pharma Acquires 80% Stake in Tergene Biotech
Aurobindo Pharma has completed the acquisition of 80% stake in Tergene Biotech, a step-down subsidiary of the company and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the company. With this, with effect from 26 February 2025, Tergene has become a direct subsidiary of the company.28 Feb, 2025 07:09 PMKotak Equities Optimistic on Indian Pharma Amid US Tariff Uncertainties
Kotak Institutional Equities noted in its report that among its formulations and biosimilars coverage, Aurobindo Pharma and Biocon lead with a US EBITDA contribution of 45-50%.27 Feb, 2025 03:06 PMImpact of Trump's Tariffs on Indian Pharma Companies
According to an HSBC report, a 10 percent tariff on pharma imports could impact the earnings of Indian pharma companies, with Aurobindo Pharma seeing a 5.5 percent reduction in its earnings per share (EPS).25 Feb, 2025 12:53 AMAurobindo Pharma Financials
Index Inclusions
Aurobindo Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 16.29% | ||
| Mutual Funds | 17.81% | ||
| Retail Investors | 6.69% | 3.51 | |
| Others | 7.4% | 11.99 |
Aurobindo Pharma Key Indicators
Aurobindo Pharma Valuation
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (17.71x)
February 28, 2025
Industry (50.30x)
February 28, 2025
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.43%.
Read More about Dividends
Aurobindo Pharma Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
Aurobindo Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹62,009.88 Cr | 22.79% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹11,541.60 Cr | -6.3% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹88,206.47 Cr | 50.09% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹64,590.76 Cr | 19.49% | 0.53 | NA | NA | |
| BUY | ₹41,933.92 Cr | 17.99% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Share Price: ₹1058.30 per share as on 28 Feb, 2025 04:01 PM
Market Capitalisation: ₹62,009.88Cr as of today
Revenue: ₹7,893.15Cr as on December 2024 (Q4 24)
Net Profit: ₹845.57Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Aurobindo Pharma Ltd
What is Aurobindo Pharma Ltd price today?
Aurobindo Pharma Ltd share price today stands at ₹1058.3, Open: ₹1075.9, Previous Close: ₹1080.7, High: ₹1076.35, Low: ₹1053.3, 52 Week High: ₹1592, 52 Week Low: ₹984.3.
How to Buy Aurobindo Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Aurobindo Pharma Ltd shares
Is Aurobindo Pharma Ltd listed on NSE?
Aurobindo Pharma Ltd is listed on NSE
Is Aurobindo Pharma Ltd listed on BSE?
Aurobindo Pharma Ltd is listed on BSE
What are today's High and Low prices of Aurobindo Pharma Ltd?
- Today's highest price of Aurobindo Pharma Ltd is ₹1076.35.
- Today's lowest price of Aurobindo Pharma Ltd is ₹1053.3.
What are today's traded volumes of Aurobindo Pharma Ltd?
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 7.95L.
What is today's market capitalisation of Aurobindo Pharma Ltd?
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹62009.88Cr.
What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?
How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1058.3. It is down -33.52% from its 52 Week High price of ₹1592
How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1058.3. It is up 7.52% from its 52 Week Low price of ₹984.3
What are the historical returns of Aurobindo Pharma Ltd?
What is the PE ratio of Aurobindo Pharma Ltd today?
PE Ratio of Aurobindo Pharma Ltd is 17.71
PE ratio = Aurobindo Pharma Ltd Market price per share / Aurobindo Pharma Ltd Earnings per share